Literature DB >> 6492081

A theoretical investigation of histamine tautomerism.

S Topiol, H Weinstein, R Osman.   

Abstract

Geometry optimizations of the structures of histamine (neutral and monocation) in the N(3)-H and N(1)-H tautomeric forms were performed at the ab initio Hartree-Fock level with the STO-3G basis set. Values of the structural parameters and their changes upon protonation and/or tautomerization are in good agreement with data from X-ray crystal-structure analysis of histamine and several analogues. Earlier predictions of the tautomeric preference from calculations using frozen geometries based on crystal-structure data are confirmed by calculations of energies of histamine in the fully optimized geometries with both the STO-3G and LP-3G basis sets and by comparisons of the minima in the molecular electrostatic potentials of the two tautomers. These results support a previously proposed model for the activation of the histamine H2 receptor.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6492081     DOI: 10.1021/jm00377a023

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  4 in total

Review 1.  Histamine receptors in the central nervous system.

Authors:  H Timmerman
Journal:  Pharm Weekbl Sci       Date:  1989-10-20

2.  The computational design of test compounds with potentially specific biological activity: histamine-H2 agonists derived from 5-HT/H2 antagonists.

Authors:  S Topiol; M Sabio
Journal:  J Comput Aided Mol Des       Date:  1991-06       Impact factor: 3.686

3.  Histamine receptor activation by unsaturated (allyl and propargyl) homologs of histamine.

Authors:  J W Banning; R K Griffith; R A Dipietro
Journal:  Agents Actions       Date:  1985-12

4.  Gas-Phase Thermal Tautomerization of Imidazole-Acetic Acid: Theoretical and Computational Investigations.

Authors:  Saadullah G Aziz; Osman I Osman; Shaaban A Elroby; Rifaat H Hilal
Journal:  Int J Mol Sci       Date:  2015-11-04       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.